Terms: = Bone cancer AND PIM1, PIM, 5292, ENSG00000137193, P11309 AND Prognosis
11 results:
1. An overview of pim kinase as a target in multiple myeloma.
Liu Z; Zhang Y; Guo Y; Wang H; Fu R
Cancer Med; 2023 May; 12(10):11746-11759. PubMed ID: 37162273
[TBL] [Abstract] [Full Text] [Related]
2. Design and synthesis of a novel mitochondria-targeted osteosarcoma theranostic agent based on a pim1 kinase inhibitor.
Yi X; Cao Z; Yuan Y; Li W; Cui X; Chen Z; Hu X; Yu A
J Control Release; 2021 Apr; 332():434-447. PubMed ID: 33662457
[TBL] [Abstract] [Full Text] [Related]
3. Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia.
Hu X; Chen F
Hematology; 2019 Dec; 24(1):651-660. PubMed ID: 31533545
[No Abstract] [Full Text] [Related]
4. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.
Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B
Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155
[TBL] [Abstract] [Full Text] [Related]
5. miR-486 inhibited osteosarcoma cells invasion and epithelial-mesenchymal transition by targeting pim1.
Liu Y; Zhang J; Xing C; Wei S; Guo N; Wang Y
Cancer Biomark; 2018; 23(2):269-277. PubMed ID: 30103304
[TBL] [Abstract] [Full Text] [Related]
6. Expression and function of pim kinases in osteosarcoma.
Mou S; Wang G; Ding D; Yu D; Pei Y; Teng S; Fu Q
Int J Oncol; 2016 Nov; 49(5):2116-2126. PubMed ID: 27826617
[TBL] [Abstract] [Full Text] [Related]
7. Clinical and biological significance of pim1 kinase in osteosarcoma.
Liao Y; Feng Y; Shen J; Gao Y; Cote G; Choy E; Harmon D; Mankin H; Hornicek F; Duan Z
J Orthop Res; 2016 Jul; 34(7):1185-94. PubMed ID: 26687194
[TBL] [Abstract] [Full Text] [Related]
8. Novel myelofibrosis treatment strategies: potential partners for combination therapies.
Stein BL; Swords R; Hochhaus A; Giles F
Leukemia; 2014 Nov; 28(11):2139-47. PubMed ID: 24888274
[TBL] [Abstract] [Full Text] [Related]
9. A potential therapeutic target for FLT3-ITD AML: pim1 kinase.
Fathi AT; Arowojolu O; Swinnen I; Sato T; Rajkhowa T; Small D; Marmsater F; Robinson JE; Gross SD; Martinson M; Allen S; Kallan NC; Levis M
Leuk Res; 2012 Feb; 36(2):224-31. PubMed ID: 21802138
[TBL] [Abstract] [Full Text] [Related]
10. Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma.
Lu XY; Lu Y; Zhao YJ; Jaeweon K; Kang J; Xiao-Nan L; Ge G; Meyer R; Perlaky L; Hicks J; Chintagumpala M; Cai WW; Ladanyi M; Gorlick R; Lau CC; Pati D; Sheldon M; Rao PH
Mol Cancer Res; 2008 Jun; 6(6):937-46. PubMed ID: 18567798
[TBL] [Abstract] [Full Text] [Related]
11. NUP98 dysregulation in myeloid leukemogenesis.
Moore MA; Chung KY; Plasilova M; Schuringa JJ; Shieh JH; Zhou P; Morrone G
Ann N Y Acad Sci; 2007 Jun; 1106():114-42. PubMed ID: 17442773
[TBL] [Abstract] [Full Text] [Related]
